Omega Therapeutics, Inc. announced new preclinical data supporting the potential of OTX-2101, a c-MYC-targeting epigenomic controller (MYC-EC) being developed for the treatment of non-small cell lung cancer (NSCLC), in combination with immune checkpoint inhibitors or EGFR inhibitors at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics which took place in Boston, Mass., October 11 -- 15, 2023. These new data build on previous results demonstrating anti-tumor activity of OTX-2101 as a monotherapy in preclinical NSCLC models and highlight its potential ability to synergize with clinically validated strategies. These encouraging results give confidence in OTX-2101's potential as meaningful new treatment option for patients living with NSCLC.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.005 USD | -4.98% | -10.31% | -33.55% |
01:00pm | Omega Therapeutics, Inc. Appoints Kaan Certel, Ph.D., as Chief Business Officer | CI |
05-06 | Omega Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-33.55% | 116M | |
+48.69% | 58.71B | |
-2.82% | 41.31B | |
+36.42% | 39.2B | |
-11.22% | 27.4B | |
+9.60% | 26.55B | |
-22.60% | 18.98B | |
+1.89% | 12.51B | |
+26.48% | 12.08B | |
+21.82% | 11.94B |
- Stock Market
- Equities
- OMGA Stock
- News Omega Therapeutics, Inc.
- Omega Therapeutics, Inc. Presents New Preclinical Data Supporting the Potential of OTX-2101 in Combination Settings for Treatment of NSCLC